Results 171 to 180 of about 72,525 (247)

Effectiveness and Safety of Imatinib and Nilotinib in Chronic Myeloid Leukemia: A Single-Center Study From Southern Morocco. [PDF]

Cureus
El Mousadik M, El Khayat H, El Hizazi L, Bounar O, Halloumi O, Fatima Ezzahra R, Chakri I, Bouqoufi A, Lahlou L, Fares S.   +9 more
europepmc   +1 more source

Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives. [PDF]

Clinicoecon Outcomes Res
Vaughn JE, Zawadzki N, Zhang S, Pinkston P, Wei D, Shafrin J.   +5 more
europepmc   +1 more source

Impact of Imatinib Therapy on Immunometabolism to Promote β-Cell Survival in Diabetes. [PDF]

J Diabetes
Kumar S, Kumari R.
europepmc   +1 more source

Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro [PDF]

, 2012
Lyons, John, Holyoake, Tessa L., Jorgensen, Heather, Shah, Mohsin, Gallipoli, Paolo   +4 more
core   +1 more source

Ru-Based Photocaged Kinase Inhibitors Operative under Deep-Red Light Irradiation. [PDF]

J Am Chem Soc
Pragti, Kundu BK, Feroz W, Garrett J, Diao J, Sun Y.   +5 more
europepmc   +1 more source

Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment. [PDF]

Cancer Res Commun
Khosroyani HM, Teuber A, Town A, Klug LR, Evans D, Call J, Rothschild S, Somaiah N, Thirasastr P, Liu M, Chi P, Hohenberger P, Rutkowski P, Schöffski P, Agaimy A, Brahmi M, Killian JK, Frampton GM, Beadling C, Bauer S, Falkenhorst J, Heinrich MC.   +21 more
europepmc   +1 more source

An unresectable desmoid tumour demonstrating long-term complete response to imatinib monotherapy: a case report. [PDF]

J Med Case Rep
Liu P, Lau YM, Charakidis M, Downton T, Byron Y, Karanth N.   +5 more
europepmc   +1 more source

Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications. [PDF]

Cancer Chemother Pharmacol
Rasmussen ASB, Rank CU, Christensen IJ, Weimann A, Hansen K, Thastrup M, Yang T, Lund TM, Wik HS, Vogt H, Norén-Nyström U, Vaitkeviciene G, Albertsen BK, Wehner PS, Als-Nielsen B, Andersen CL, Dalhoff K, Schmiegelow K.   +17 more
europepmc   +1 more source

Exceptional therapeutic benefit of imatinib in cKIT‐mutated mucosal melanoma followed by a KIT mutation loss

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 9, Page 1311-1313, September 2026.
Hannah Zillikens, Corinna Scheib, Vicky Peller, Christina Müller, Sebastian Bauer, Ina Pretzell, Klaus Griewank, Antje Sucker, Eva Hadaschik, Felicitas Guntrum, Sven Holger Baum, Alexander Roesch, Selma Ugurel, Dirk Schadendorf, Lisa Zimmer, Elisabeth Livingstone   +15 more
wiley   +1 more source

Treatment patterns and outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia: a single center study from Oman. [PDF]

Front Oncol
Al-Rawahi N, Salman B, Meenakshi DU, Al-Khabori M, Al-Hanini M, Al-Kindi S.   +5 more
europepmc   +1 more source